Clinical tests L.php?campaign=WP%20Disease%20Registries%20Track%20Bett.

Slides:

Advertisements

Similar presentations

Fundamentals of Clinical Trials

Advertisements

Figure ES-1. Select Practice* over Time Percent of hospitals * Hospitals in the top two quintiles for both quality and efficiency. Source: Authors’ analysis.

Organizational Consulting Center Business Plan Presented By: Eric Bunyan, Nikki Prestidge, Danny Seto Shayna Slebioda, & Pegah Soleimani.

Preventable Hospitalizations: Assessing Access and the Performance of Local Safety Net Presented by Yu Fang (Frances) Lee Feb. 9 th, 2007.

Community-based Clinical Trials: Site Variation and Adoption of Innovation Dennis McCarty, PhD Allie Buti, MPH Lynn Kunkel, MS, CCRP Holly Fussell, PhD.

Diabetes Hospital Discharge and Emergency Department Data, Montana Dorota Carpenedo, MPH Epidemiologist

Increasing Health Care Costs: the Price of Innovation? AcademyHealth Annual Research Meeting June 7, 2004 Claudia A. Steiner, MD, MPH Bernard Friedman,

DATA Role of data in QI and Scholarship Characteristics of “good” data Sources/categories of data Administrative databases – pros &cons New Informatics.

INTRODUCTION TO TBI DATABASE RESEARCH Juan Carlos Arango, Ph.D Virginia Commonwealth University Medical Center.

Three Options Direct hospital participation Third party submits data for hospitals according to new policies.

Urologic Diseases in America Available Datasets. Urologic Diseases in America Mission: 1. Define the burden of illness posed on the nation by the major.

A novel node in the Learning Health Care System December 2014

Personal Characteristics Genetics Race Gender Age Personality.

The Redesigned National Hospital Discharge Survey National Center for Health Statistics Division of Health Care Statistics Hospital Care Team Last Updated:

Marketing Information and Research

Using OSHPD Data to Understand Health and Healthcare Patterns: Descriptive Reports and Research Briefs Presenter: Mary Tran, PhD, MPH.

THE PREVALENCE AND PREDICTORS OF LOW-COST GENERIC PROGRAM USE IN A NATIONALLY REPRESENTATIVE ADULT POPULATION: IMPLICATIONS FOR PATIENTS, RESEARCH, AND.

Making patients’ views count Frequent Feedback Service Regula Dent Marketing Manager Picker Institute 21 April 2009.

Assessing The Value of Web 2.0 on Knowledge Management A HEALTH CARE REIMBURSEMENT STUDY ICELW CONFERENCE JUNE 2013.

Can high healthcare costs be reduced? - Empirical evidence from community hospitals Haichang Xin 1, PhD, Mark L. Diana 2, PhD, Anjum Khurshid 3, PhD, Lisanne.

CARDIOVASCULAR DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.

1 Session 3 Basic Results Database Deborah A. Zarin, M.D. Background Specific Results Data Elements Data Entry and Display Mockups.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care A Web-Based Tool for Quality and Utilization Reporting Visit.

Serbia Health Project – Additional Financing Training for Trainers on AR-DRG, Република Србија МИНИСТАРСТВО ЗДРАВЉА Prof Ric Marshall Interim.

1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.

Breast Cancer and Autologous Bone Marrow Transplantation in the United States Prof Cindy Farquhar MD MPH University of Auckland, NZ.

Example of Medical Record Elements

Snapshot of IMS LifeLink Claims Database 10% Random Sample

Medicines Differentiation Analysis Multiple Sclerosis 18 January 2011 Mary Perkins Expected Launch Date: 3/31/2013.

Versie xxx. Bijgewerkt op :45 door xxx 1 Evt. klantlogo 1 x 3,56 cm Benchmarking High-Value Healthcare With Web-Based MIS Marc Berg Erik-Jan.

County of San Diego Division of Emergency Medical Services EMS 1 Mental Health Disorders and Substance Use and Abuse in the Emergency Department County.

State Hospice Organization Report Medicare 2012 Hospice Utilization 1/30/14 Please contact Cordt Kassner, PhD, at Hospice Analytics with any questions,

The Quality of Reporting on Race & Ethnicity in US Hospital Discharge Abstract Data Roxanne Andrews, PhD June 10, 2008.

July 31, 2009Prepared by the Maine Health Information Center Overview of All Payer Claims Data Suanne Singer, Senior Consultant Maine Health Information.

California Perspectives In Healthcare Presenter: Charlene Parham.

Specific Aim 1: Determine the impact of psychiatric disorders on the hospital length of stay (LOS) in pediatric patients diagnosed with SCD admitted for.

Hospitalizations Due to Severe Hypoglycemia in Patients with Type 1 Diabetes Mellitus: US National Perspective Singh G, Mithal A, Mannalithara A, Sehgal.

Statistics for Business and Economics Chapter 1 Statistics, Data, & Statistical Thinking.

Medicines Differentiation Analysis MyCore 18 January 2011.

Introduction Biostatistics Analysis: Lecture 1 Definitions and Data Collection.

Studying Injuries Using the National Hospital Discharge Survey Marni Hall, Ph.D. Hospital Care Statistics Branch, Division of Health Care Statistics.

Medicine Differentiation Analytics Process Presentation to…. Date….

Agency for Healthcare Research and Quality Advancing Excellence in Health Care A Web-Based Tool for Quality and Utilization Reporting Anne.

Market Share System© A product offered by HerveyWerks.

Introduction to Statistical Computing Methods in Clinical Research July 2000.

Local Area Network (LAN) Database Asset Manager Application Server.

Vermont Explor Data & Planning Vermont Technical College March 14 th, 2005.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care A Web-Based Tool for Quality and.

Elsevier items and derived items © 2007 by Saunders, an imprint of Elsevier Inc. Chapter 9 Statistics.

The National Hospital Care Survey Linda McCaig, M.P.H. National Center for Health Statistics August 8, 2012.

Marketing Terms Marketing Plan Product Mix Marketing Objectives Channel of Distribution Marketing Mix Intermediaries Brand Package Label Product Positioning.

Medicines Differentiation Analytics Increasing Pipeline Returns Medicines Differentiation Analytics Methodology Review with ……. Date, 2011 Add any Logo.

Chapter 7: Indexes, Registers, and Health Data Collection

Hospital racial segregation and racial disparity in mortality after injury Melanie Arthur University of Alaska Fairbanks.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care A Web-Based Tool for Quality and Utilization Reporting Visit.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 14: End-of-life Care for Patients with End-Stage Renal Disease:

Medicines Differentiation Analysis MyCore 18 January 2011 Mary Patterson Expected Launch Date: 6/1/2012.

Improving Care Coordination and Readmissions Using Real Time Predictive Analytics from an HIE New Jersey / Delaware Valley HIMSS Conference Atlantic City,

Marketing Plans Business Plan Demographics Price Market Segmentation SWOT Goals / Objectives Market Marketing Mix / 4Ps Target Market Product Geographics.

List of assets currently in the system. Tabs allow you to navigate to different sections of system (screens) Asset information: -Therapeutic category/disease.

Database Implementation The Brick Tavern Inn Alonzo Harding, Eric Lukens, Tony Wu.

Department of Public Health Medically Indigent Care Reporting System (MICRS) Medically Indigent Services Program (MISP) 1.

Scheme of Work WeekTopic 1 Introduction: The Marketing & Marketing Mix; 7 P’s 2 The fundamental Promotion: Segmentation, Targeting, Positioning; Promotion.

Chapter 8: Marketing Marketing Concepts Place (Channels of Distribution) Channels of distribution are the paths of ownership that goods follow as they.

Acute Renal Failure in Aneurysmal Subarachnoid Hemorrhage: Nationwide Analysis of Hospitalizations in the United States Kavelin Rumalla 1, Adithi Y. Reddy.

Introduction to Health Insurance

2016 Annual Data Report, Vol 2, ESRD, Ch 14

2014 Medicare Information With 2013 Comparisons

Trauma Data Elements Recommended by RSWG for Inclusion into the Texas Trauma Registry Stakeholder Webinar.

Hospitalization rates of children diagnosed with a single CCC and children diagnosed with more than 1 CCC. Hospitalization rates were adjusted for race,

Presentation transcript:

Clinical tests L.php?campaign=WP%20Disease%20Registries%20Track%20Bett er%20Healthcare%20L&confirmation=Perfect-Storm-Secondary- Offer-Dynamic.php&gclid=CLiE4IbTi6oCFQIFbAodfn5vyg Clinical research data & software tools planned-comparative-effectiveness-database/ CER database (intended) (HHS) data elements Primary and secondary diagnoses Primary and secondary procedures Admission and discharge status Patient demographics (e.g., gender, age, race, median income for ZIP Code) Expected payment source Total charges Length of stay Hospital characteristics (e.g., ownership, size, teaching status). m?fuseaction=Search.Search_Drug_Name FDA Drug Database Healthcare Databases

Competitive Products CompetitorProductDisease Area Development PhaseRigor Score Rigor Comments Standard Of Care?Approval Date Expiration Date Merck SeronoRebifNovel MS Peptide (NMP) In-Line NovartisGilenya/Fingol imod Novel MS Peptide (NMP) In-Line TevaCopaxoneNovel MS Peptide (NMP) In-Line Biogen IdecTysabriNovel MS Peptide (NMP) In-Line Biogen IdecBG-12Novel MS Peptide (NMP) Pipeline TevaLaquinimodNovel MS Peptide (NMP) Pipeline Sanofi/Genzy me LemtradaNovel MS Peptide (NMP) Pipeline Specific Parameter Performance data – can not be in this table because there are multiple parameters for ach disease area & single drug can server multiple disease areas.

Parameters Disease Area Parame ter Categor y Paramete r Title Scale Type Low Edn High End # Tick Marks Tick 1 Tick 2 Tick 3 Tick 4 Tick 5 Tick 6 Tick 7 # Deci mal Plac es Des crip tion of Unit s Scal e Des crip tion Novel MS Peptide (NMP) EfficacyReduction in Relapse Rate Perce ntage 20%50%135 % Novel MS Peptide (NMP) EfficacyReduction in Progressi on of Disability Rate Novel MS Peptide (NMP) Tolerabi lity Ability to Stay on Treatmen t Novel MS Peptide (NMP) Conveni ence Administr ation Novel MS Peptide (NMP) CostAnnual Cost Novel MS Peptide (NMP) SafetyAdverse Events Parameter Category Efficacy Safety Tolerability Convenience Cost Scale Type Numeric Percentage Date Time Choices

Mountain Top Competitor Data Parameters (by Disease Area) Drug Performance Data (HDI) Pharmaceutical companies for pipeline management VC companies to value assets Payers (consistent valuation based on drug performance) Consulting Companies (to support clients better)

Path Prototype Collect Data Develop Capability Mountain Top July 2011 Access to clients to collect data VC External IT development External research team Offer to public Production/ Market